May 15, 2023
New Sandoz Board of Directors appointed
Sandoz takes the next steps to prepare for the planned listing on the Swiss Stock Exchange (SIX): The Novartis Board of Directors has approved the recommendations of the Sandoz Chairman-designate, Gilbert Ghostine, on the structure of the to-be Board of Directors of Sandoz and has nominated all of its future members.
April 25, 2023
Sandoz planned spin-off updates at Novartis Q1 2023 Financial Results
The planned spin-off remains on track for the second half of 2023. Completion of the transaction is subject to certain conditions, including consultation with works councils and employee representatives (as required), general market conditions, tax rulings and opinions, final Board of Directors endorsement and shareholder approval in line with Swiss corporate law. The transaction is expected to be tax neutral to Novartis.
Sandoz Capital Markets Day for investors will take place on June 8, 2023 (New York, USA) and June 12, 2023 (London, UK)
Feb 20, 2023
Novartis announces the appointment of the Chairman-Designate of Sandoz Board of Directors
Read the full media release: English
Aug 25, 2022
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
Read the full media release: English | German
Investors
Watch the webcast
16:00 CEST | 15:00 BST | 10:00 EDT
Download the presentation (PDF 1.1 MB)